{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:01:25Z","timestamp":1775545285677,"version":"3.50.1"},"reference-count":23,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMJ"],"DOI":"10.4274\/mmj.galenos.2024.94884","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T07:23:01Z","timestamp":1731655381000},"source":"Crossref","is-referenced-by-count":1,"title":["The Serum Biomarkers in Ulcerative Colitis"],"prefix":"10.4274","author":[{"given":"Semih","family":"SEZER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"DEMIRCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa Irem","family":"KARA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"KORKMAZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","unstructured":"1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-78.","journal-title":"N Engl J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12328-008-0018-z","article-title":"A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index","volume":"1","author":"Hirai","year":"2008","unstructured":"2. Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol. 2008;1:40-5.","journal-title":"Clin J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649-70. Erratum in: J Crohns Colitis. 2023;17:149.","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"Third European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","unstructured":"4. Gomoll\u00f3n F, Dignass A, Annese V, et al. Third European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3-25.","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/diagnostics10060367","article-title":"Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults","volume":"10","author":"Krzystek-Korpacka","year":"2020","unstructured":"5. Krzystek-Korpacka M, Kempi\u0144ski R, Bromke M, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics (Basel). 2020;10:367.","journal-title":"Diagnostics (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1097\/MIB.0000000000000903","article-title":"New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes","volume":"22","author":"EL","year":"2016","unstructured":"6. Barnes EL, Burakoff R. New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes. Inflamm Bowel Dis. 2016;22:2956-65.","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","unstructured":"7. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5-14."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.surg.2007.12.014","article-title":"The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer","volume":"143","author":"Smith","year":"2008","unstructured":"8. Smith RA, Bosonnet L, Ghaneh P, et al. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery. 2008;143:658-66.","journal-title":"Surgery"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7861\/clinmedicine.9-1-30","article-title":"Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein\/albumin ratio as a predictor of patient outcome","volume":"9","author":"Fairclough","year":"2009","unstructured":"9. Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein\/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 2009;9:30-3.","journal-title":"Clin Med (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000510963","article-title":"C-reactive protein-lymphocyte ratio identifies patients at low risk for major morbidity after oesophagogastric resection for cancer","volume":"37","author":"Neary","year":"2020","unstructured":"10. Neary C, McAnena P, McAnena O, et al. C-reactive protein-lymphocyte ratio identifies patients at low risk for major morbidity after oesophagogastric resection for cancer. Dig Surg. 2020;37:515-23.","journal-title":"Dig Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","unstructured":"11. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-6.","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Cohen J. Statistical power analysis for the behavioral sciences: routledge; 2013.","DOI":"10.4324\/9780203771587"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ni.1659","article-title":"Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset","volume":"9","author":"Veldhoen","year":"2008","unstructured":"13. Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9:1341-6.","journal-title":"Nat Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/ni.1677","article-title":"IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells","volume":"9","author":"Dardalhon","year":"2008","unstructured":"14. Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol. 2008;9:1347-55.","journal-title":"Nat Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/107999099313604","article-title":"Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease","volume":"19","author":"Heits","year":"1999","unstructured":"15. Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999;19:757-60.","journal-title":"J Interferon Cytokine Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1572-0241.2004.04129.x","article-title":"Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications","volume":"99","author":"Danese","year":"2004","unstructured":"16. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004;99:938-45.","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1572-0241.2001.03621.x","article-title":"Mean platelet volume: a useful marker of inflammatory bowel disease activity","volume":"96","author":"Kapsoritakis","year":"2001","unstructured":"17. Kapsoritakis AN, Koukourakis MI, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96:776-81.","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005;39(4 Suppl 2):S143-6.","DOI":"10.1097\/01.mcg.0000155514.17715.39"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Tominaga T, Nonaka T, Sumida Y, et al. The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients. PLoS One. 2016;11:e0167967.","DOI":"10.1371\/journal.pone.0167967"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"851295","DOI":"10.3389\/fpubh.2022.851295","article-title":"Inflammatory indexes for assessing the severity and disease progression of ulcerative colitis: a single-center retrospective study","volume":"10","author":"Lin","year":"2022","unstructured":"20. Lin H, Bai Z, Wu Q, et al. Inflammatory indexes for assessing the severity and disease progression of ulcerative colitis: a single-center retrospective study. Front Public Health. 2022;10:851295.","journal-title":"Front Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1349070","DOI":"10.3389\/fmed.2024.1349070","article-title":"C-reactive protein-to-albumin ratio and neutrophil-to-albumin ratio for predicting response and prognosis to infliximab in ulcerative colitis","volume":"11","author":"Zhang","year":"2024","unstructured":"21. Zhang Y, Xu F, Li Y, et al. C-reactive protein-to-albumin ratio and neutrophil-to-albumin ratio for predicting response and prognosis to infliximab in ulcerative colitis. Front Med (Lausanne). 2024;11:1349070.","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12876-022-02571-9","article-title":"Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study","volume":"22","author":"Feng","year":"2022","unstructured":"22. Feng W, Liu Y, Zhu L, et al. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study. BMC Gastroenterol. 2022;22:485.","journal-title":"BMC Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11:49-54.e1.","DOI":"10.1016\/j.cgh.2012.08.003"}],"container-title":["Medeniyet Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:04:18Z","timestamp":1775541858000},"score":1,"resource":{"primary":{"URL":"https:\/\/medeniyetmedicaljournal.org\/articles\/doi\/MMJ.galenos.2024.94884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":23,"URL":"https:\/\/doi.org\/10.4274\/mmj.galenos.2024.94884","relation":{},"ISSN":["2149-2042"],"issn-type":[{"value":"2149-2042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}